Craig Bennison
Overview
Explore the profile of Craig Bennison including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
210
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Takeshima T, Sakai F, Wang X, Yamato K, Kojima Y, Zhang Y, et al.
Pharmacoeconomics
. 2024 May;
42(7):811-822.
PMID: 38771521
Background And Objectives: Fremanezumab is an effective treatment for episodic (EM) and chronic migraine (CM) patients in Japan, but its cost effectiveness remains unknown. The objective of this study was...
2.
Simons C, Hwu W, Zhang R, Simons M, Bergkvist M, Bennison C
Adv Ther
. 2023 Oct;
40(12):5399-5414.
PMID: 37803205
Introduction: Aromatic L-amino acid decarboxylase (AADC) deficiency is a rare disease with symptoms including movement disorders, developmental delays, and autonomic symptoms starting from birth; further, patients with AADC deficiency are...
3.
Wang X, Yamato K, Kojima Y, Paris J, Peterse E, Simons M, et al.
Pharmacoeconomics
. 2023 Jun;
41(10):1263-1274.
PMID: 37318748
Background And Objectives: As regression approaches have been used more recently to model the effectiveness and health-related quality of life (HRQOL) of novel migraine treatments, an example is provided for...
4.
Piena M, Houwing N, Kraan C, Wang X, Waters H, Bennison C
Pharmacoeconomics
. 2022 Nov;
40(12):1265-1267.
PMID: 36357767
No abstract available.
5.
Petersohn S, Salles G, Wang M, Wu J, Wade S, Simons C, et al.
J Med Econ
. 2022 May;
25(1):730-740.
PMID: 35611697
Aims: The objective of this study is to estimate the cost-effectiveness of KTE-X19 versus standard of care (SoC) in the treatment of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL)...
6.
Barbier M, Durno N, Bennison C, Ortli M, Knapp C, Schwenkglenks M
Eur J Health Econ
. 2021 Nov;
23(5):837-846.
PMID: 34757508
Introduction: Venetoclax in combination with rituximab (VEN + R) demonstrated prolonged overall survival (OS) and progression-free survival (PFS) for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) in comparison to...
7.
Piena M, Houwing N, Kraan C, Wang X, Waters H, Duffy R, et al.
Pharmacoeconomics
. 2021 Oct;
40(1):121-131.
PMID: 34622429
Introduction: Schizophrenia is a chronic mental disorder that worsens with each relapse. Long-acting injectable (LAI) antipsychotics may prevent the exacerbation of symptoms and occurrence of relapses through improved continuity of...
8.
Simons C, Malone D, Wang M, Maglinte G, Inocencio T, Wade S, et al.
J Med Econ
. 2021 Feb;
24(1):421-431.
PMID: 33634729
Aims: The objective of this study is to estimate the cost-effectiveness of KTE-X19 versus standard of care (SoC) in the treatment of relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients from...
9.
Di Tanna G, Urbich M, Wirtz H, Potrata B, Heisen M, Bennison C, et al.
Pharmacoeconomics
. 2020 Nov;
39(2):211-229.
PMID: 33251572
Background And Objectives: New treatments and interventions are in development to address clinical needs in heart failure. To support decision making on reimbursement, cost-effectiveness analyses are frequently required. A systematic...
10.
Urbich M, Globe G, Pantiri K, Heisen M, Bennison C, Wirtz H, et al.
Pharmacoeconomics
. 2020 Aug;
38(11):1219-1236.
PMID: 32812149
Background: Heart failure presents a growing clinical and economic burden in the USA. Robust cost data on the burden of illness are critical to inform economic evaluations of new therapeutic...